View Older Stories

Jan 20, 2026 09:00AM Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following l

Jan 13, 2026 04:15PM Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Jan 12, 2026 08:00AM Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Dec 18, 2025 09:00AM Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

Dec 15, 2025 09:01AM Aytu BioPharma launches EXXUA for major depressive disorder treatment

Dec 15, 2025 09:00AM Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Dec 10, 2025 03:55AM Aytu Biosciences (AYTU) PT Raised to $13 at Ascendiant Capital

Nov 24, 2025 04:05PM Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 13, 2025 05:31PM Aytu BioScience (AYTU) Tops Q1 EPS by 21c

Nov 13, 2025 04:05PM Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025 04:05PM Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Oct 28, 2025 09:01AM Aytu BioPharma receives patent extension for EXXUA through 2030

Oct 28, 2025 09:00AM Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 10, 2025 09:00AM Aytu BioPharma to Present at Upcoming October 2025 Conferences

Sep 24, 2025 04:15PM Aytu BioPharma to Present at Upcoming September 2025 Conferences

Sep 23, 2025 04:05PM Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025 04:05PM Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Jul 1, 2025 08:56AM Lake Street Capital Markets Starts Aytu Biosciences (AYTU) at Buy

Jun 30, 2025 03:25AM Ascendiant Capital Starts Aytu Biosciences (AYTU) at Buy

Jun 25, 2025 08:00AM Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Jun 23, 2025 08:05AM Aytu BioScience (AYTU) Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA

Jun 23, 2025 08:00AM Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 9, 2025 04:30PM Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opp

Jun 6, 2025 08:15AM Aytu BioScience (AYTU) Prices Upsized 9.6M Share Offering at $1.50/sh

Jun 6, 2025 08:01AM Aytu BioScience (AYTU) Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA

Jun 6, 2025 08:01AM Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025 08:00AM Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

May 14, 2025 06:13PM Aytu BioScience (AYTU) Tops Q1 EPS by 65c

May 14, 2025 04:05PM Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025 04:15PM Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 21, 2025 04:05PM Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Feb 12, 2025 04:03PM Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 5, 2025 05:50PM Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025 09:00AM Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024 11:45PM Aytu BioPharma Disclosure Notification

Nov 22, 2024 09:00AM Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024 04:05PM Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024 05:20PM Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 14, 2024 04:15PM Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024 12:00PM Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Oct 1, 2024 08:02AM Aytu BioScience (AYTU) Announces Exclusive Agreement with Lupin Pharma Canada to Commercialize Adzenys XR-ODT and Cotempla XR-ODT

Sep 26, 2024 04:36PM Aytu BioScience (AYTU) Files $100M Mixed Shelf

Sep 26, 2024 04:15PM Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 16, 2024 11:47PM Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 8, 2024 05:20PM Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024 08:13AM Aytu BioScience (AYTU) Sells Consumer Health Business Following Wind Down of Consumer Health Operations

Aug 6, 2024 08:00AM Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024 08:02AM Aytu BioScience (AYTU) Announces Paydown and Refinancing of Term Loan

Jun 18, 2024 08:00AM Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

View Older Stories